Advertisement
News
Advertisement

Organovo Appoints Dr. Eric Michael David As Chief Strategy Officer

Mon, 05/21/2012 - 4:46am
The Associated Press

Organovo Holdings, Inc.

(OTCQB: ONVO) ("Organovo"), a biotechnology company focused on delivering breakthrough three-dimensional (3D) bioprinting technology, today announced the appointment of Eric Michael David, M.D., J.D., as chief strategy officer. Dr. David was most recently associate partner at the consultancy McKinsey & Company, where he served private equity, pharmaceutical, biotech, diagnostic, and medical device clients to support pipeline and R&D strategy, as well as market entry strategy.

Organovo is developing bioprinting across a broad array of cell types to create functional 3D tissues that can recapitulate in vivo biology for human disease research, drug discovery and development, toxicology testing and, eventually, as therapies. "Eric has deep strategic expertise and experience in developing product pipelines and partnerships that advance innovation for breakthrough medical impact," said Chief Executive Officer Keith Murphy. "His training in research, medicine and law, coupled with more than six years of top-level strategy consulting, will help Organovo in the company's mission to deliver breakthrough bioprinting technology for research and medical applications." Dr. David played a critical role in the commercial translation of 3D bioprinting as a founder and early director of Organovo, Inc.  Prior to his time at McKinsey, Dr. David served as a freelance consultant to the Department of Health and Human Services in the use of genomic technologies for early detection of pathogens for public health preparedness. He completed his residency in Internal Medicine at New York Presbyterian Hospital, where he served as Assistant Chief Resident and received the Dick Bowman Award for scientific endeavor and dedication to patient care. He was also Assistant Professor at The Rogosin Institute and adjunct faculty at The Rockefeller University.

He received his M.D. from Columbia University College of Physicians and Surgeons, his J.D. from Columbia University School of Law, and a B.A.in physics and fine arts from Amherst College. He is board certified in Internal Medicine and admitted to the Bar in New York State.

About Organovo Holdings, Inc.

Organovo (OTCQB: ONVO) is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. The company's NovoGen three-dimensional bioprinting technology is a platform that works across all tissue and cell types. Organovo's NovoGen MMX Bioprinter(TM) was selected as one of the "Best Inventions of 2010" by TIME Magazine. Organovo is helping pharmaceutical partners develop human biological disease models in three dimensions that enable therapeutic drug discovery and development. Organovo's bioprinting technology can also be developed to create surgical tissues as direct therapy. Organovo leads the way in solving complex medical research problems and building the future of medicine. For more information, please visit http://www.organovo.com.

Safe Harbor Statement Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our Form 10-Q for the quarter ended March 31, 2012 and our Current Report on Form 8-K filed with the SEC on May 11, 2012. We do not undertake to update these forward-looking statements made by us.

SOURCE Organovo Holdings, Inc.

-0- 05/21/2012 /CONTACT: Investors, Barry Michaels, Chief Financial Officer, +1-858-224-1003, bmichaels@organovo.com, or Media, Jessica Yingling, Ph.D., Organovo Communications, +1-858-344-8091, jyingling@organovo.com, both of Organovo Holdings, Inc.

/Web Site: http://www.organovo.com (OTC-PINK:ONVO) / CO: Organovo Holdings, Inc.

ST: California IN: HEA MTC BIO SU: PER PRN -- LA10562 -- 0000 05/21/2012 12:05:00 EDT http://www.prnewswire.c

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading